Should I Buy OKUR? OKUR 2026 Analysis

Should You Buy Onkure Therapeutics Inc (OKUR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

2.500

1 Day change

7.76%

52 Week Range

6.180

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient trader: technicals remain bearish despite being oversold, and there are no proprietary buy signals.
Price is sitting just below/at key support (~2.32) with momentum still deteriorating; risk of another leg down is elevated near-term.
With no recent news catalysts and earnings coming (2026-02-12 AH), the next meaningful move is more likely event-driven than trend-supported.

Intellectia Proprietary Trading Signals

AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend/Momentum: Bearish. MACD histogram is negative (-0.0625) and expanding downward, signaling weakening momentum.
RSI (6): 16.485 (deep oversold). This can trigger sharp bounces, but oversold alone is not a buy signal when MACD is still worsening.
Moving averages: Converging, suggesting indecision/transition, but not yet a confirmed reversal.
Key levels: Current price 2.31 is slightly below S1 (2.324). If it fails to reclaim/hold this area, next support is S2 (2.092). Upside resistance starts around Pivot 2.698 then R1 3.072.
Pattern-based forward odds: Model shows ~50% chance of -1.56% next day and -4.66% next week, with a potential +3.34% next month—near-term bias still skewed down.

Positive Catalysts

- Deeply oversold RSI raises the odds of a short-term relief bounce if support reclaims above ~2.32 and holds.
- Earnings date upcoming (2026-02-12 After Hours) can act as a volatility catalyst.
- No notable recent insider or hedge fund selling pressure indicated (both described as neutral).

Neutral/Negative Catalysts

- Momentum is actively deteriorating (negative and expanding MACD histogram), often overpowering oversold signals.
- Price is trading at/just below an identified support (S1 2.324); failure to reclaim it can accelerate downside toward S2 (~2.09).
- No recent news flow to reverse sentiment; micro-cap profile (market cap noted ~$30.21M) can increase downside air pockets.
- Near-term statistical trend snapshot points to likely weakness over the next week.

Financial Performance

Latest quarter: 2025/Q3.
Revenue: 0 (no operating revenue; unchanged YoY).
Profitability: Net income reported at -14.699M (still a sizable loss); EPS at -1.09 (worse YoY per snapshot).
Overall: Financials reflect an early-stage/clinical-style profile with ongoing losses and no revenue base—price action will likely be sentiment/catalyst driven rather than fundamentals-driven in the near term.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating trend or price target changes were provided in the data.
Wall Street pros/cons view (based on available info):
- Pros: Potential upside is mostly catalyst-driven (e.g., earnings/updates) and oversold conditions can spark short squeezes/bounces.
- Cons: Lack of revenue, ongoing losses, and weakening technical momentum make it hard to justify an immediate buy without a confirmed reversal signal.

4 Analyst Rating

Wall Street analysts forecast OKUR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OKUR is 25.5 USD with a low forecast of 17 USD and a high forecast of 34 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 2.320

Low

Averages

25.5

High

Current: 2.320

Low

Averages

25.5

High

HC Wainwright & Co.

Robert Burns

Strong Buy

Maintains

$40 → $34

AI Analysis

2025-03-18

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$40 → $34

AI Analysis

2025-03-18

Maintains

Strong Buy

Reason

Oppenheimer

Matt Biegler

Buy

Maintains

$35 → $30

2025-03-11

Reason

Oppenheimer

Matt Biegler

Price Target

$35 → $30

2025-03-11

Maintains

Buy

Reason

Oppenheimer lowered the firm's price target on OnKure Therapeutics to $30 from $35 but keeps an Outperform rating on the shares after its Q4 results. The firm's post-earnings discussion with the company revealed that an important update from PIKture-01 is slated for the second half of 2025 and should provide enough data to make a determination on OKI-219's competitive profile relative to RLY-2608 and STX-478, the analyst tells investors in a research note. While OKI-219 is ultra-selective for common H1047R mutant, the company is also being more vocal about its pan-mutant inhibitor pipeline, the firm adds.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for OKUR

Unlock Now

OKUR Should I Buy

OKUR Should I Buy

Should You Buy Onkure Therapeutics Inc (OKUR) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch